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Summary Mathematical models have predicted that targeted radiotherapy of neuroblastoma with meta-
iodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 'l'I is the
conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the
hypothesis that smaller tumours of sub-millimetre dimensions are relatively resistant to '3II-mIBG. Spheroids
of the human neuroblastoma cell line SK-N-BE(2c), either 250 gsm or 400 iLm diameter, were incubated with
'11-mIBG at concentrations of up to 6.0 MBq ml-'. Using both regrowth delay and spheroid 'cure' as
endpoints, the greater vulnerability of larger spheroids was confirmed. From this in vitro result we conclude
that when used in vivo '3II-mIBG may spare smaller micrometastases. Therefore, either a radionuclide such as
21'At which emits a shorter path length radiation should be conjugated to mIBG, or targeted radiotherapy
should be combined with a treatment such as total body irradiation, the efficacy of which is not reduced in
smaller tumours.
Meta-iodobenzylguanidine (mIBG) was initially developed as
a scintigraphic agent to allow imaging of the adrenal medulla
(Wieland et al., 1980). The concept of targeted radionuclide
therapy for neuroblastoma with '311-mIBG follows naturally
from its successful use in the diagnosis and staging of
phaeochromocytoma, neuroblastoma and other tumours of
neural crest origin (Hoefnagel et al., 1987). As the uptake of
mIBG by neuroblastoma varies considerably from one
patient to another (Moyes et al., 1989), targeted radiotherapy
by itself seems unlikely to be an adequate treatment, yet it is
apparent from the considerable experience which has accrued
from its use in children with relapsed or refractory neuroblas-
toma, that it is a valuable addition to the therapeutic
armamentarium (Lewis et al., 1991, Vofite et al., 1991). The
most appropriate combination and optimal scheduling of
mIBG with chemotherapy, external beam radiotherapy and
surgery has yet to be determined.
In most circumstances, smaller volumes of tumour are
more easily eradicated than larger masses by both radio-
therapy and chemotherapy. The reasons for this are complex.
While it is principally due to the greater number of clono-
genic cells in larger tumours, poorer penetration of drugs and
the presence of hypoxic cells may also make larger tumours
more resistant to the effects of chemotherapy and radio-
therapy respectively. The decreasing probability of cure with
a given radiation dose in increasingly large tumours has been
calculated, taking into account the number of clonogenic
cells, but not considering any protective effect due to hypoxia
(Wheldon et al., 1991).
In the case of targeted radiotherapy, other factors are
pertinent. These include the penetration of the radiopharma-
ceutical, the proportion of tumour cells which are targeted,
the intracellular localisation of the targeting agent, the reten-
tion of the radiopharmaceutical, the half-life of the
conjugated radionuclide, and the physical properties of the
emitted radiation. This radiation may be characterised in
terms of its type, whether alpha and beta particles, gamma
rays or Auger electrons, and in terms of its path length. It is
the path length which is of greatest relevance when consider-
ing the likely effect on micrometastases of different sizes.
In targeted radiotherapy with mIBG it has been suggested
that smaller tumours might be more difficult to eradicate if
the conjugated radionuclide is "'lI, at least within the micro-
tumour size range up to about 1 mm, and assuming uniform
distribution of the radionuclide (O'Donoghue et al., 1991,
Wheldon et al., 1991). The explanation for this paradox -
that smaller neuroblastoma tumours might be more difficult
to cure with '311-mIBG - lies in the physical characteristics of
the radiation emitted by '3'I (Humm, 1986). As the mean
path length of its beta particles is 800 gLm, virtually all the
beta particle energy released by the disintegration of '"'I
evenly spread throughout a spherical tumour is absorbed
within that tumour if its diameter is greater than 20 mm and
a progressively smaller fraction is absorbed if its diameter is
less. The calculated fraction of absorbed energy, 0, for
tumours between 200 ym and 1000 ttm is shown in Figure 1.
In tumours larger than about 1 mm, the benefit of increased
energy absorption is offset by increasing clonogenic cell
number. The 'optimal tumour size' for 1311 therapy is cal-
culated to be 1-2mm (Wheldon et al., 1991).
There is clearly a balance between these microdosimetric
considerations which predict the relative resistance of smaller
tumour deposits to targeted therapy, and the clonogenic cell
number and other factors which make larger tumours more
resistant. A mathematical model has been developed to con-
sider the likely relative importance of these factors in deter-
mining the probability of cure of tumours of different sizes
(Wheldon et al., 1991). This has predicted that the micro-
dosimetric factor will be of greater importance in micro-
metastases, with the result that very small tumours will be
less easy to cure. The aim of the present study was to test the
prediction that very small tumours are relatively resistant to
'1g-mIBG therapy.
Multicellular spheroids of human neuroblastoma cells have
been shown to be a useful in vitro model for the assessment
of targeted radiotherapy with monoclonal antibodies (Walker
et al., 1988). The aim of the present study was to determine,
using this model, whether the size of neuroblastoma micro-
metastases is an important factor in the efficacy of mIBG
therapy, as predicted by microdosimetric calculations.
Materials and methods
Cell lines
The human neuroblastoma cell line used in this study was
SK-N-BE(2c), although NB1-G (Carachi et al., 1987) was the
line used in the original description ofthe spheroid model for
the assessment of targeted therapy (Walker et al., 1988).
SK-N-BE(2c) was derived from the bone marrow of a patient
with progressive neuroblastoma following treatment with
radiotherapy and chemotherapy (Biedler et al., 1978). This
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Figure 1 The fraction of energy absorbed within the tumour
following the decay of 13'I uniformly distributed throughout
spheroids of varying size.
cell line was chosen because it exhibits a greater degree of
active uptake of mIBG (Lashford et al., 1991; Montaldo et
al., 1991) than NBI-G (Mairs et al., 1991b).
Culture conditions
SK-N-BE(2c) was grown at 370 in 5% CO2 in RPMI 1640
medium containing 25 mM Hepes buffer and supplemented
with 15% foetal calf serum, 2 mM glutamine, penicillin/
streptomycin (100 IU ml-'), amphotericin B (2.5 fg ml-')
and non-essential amino acids. All media and supplements
were obtained from Gibco (Paisley, UK). Multicellular
tumour spheroids were prepared by continuous stirring at
0.5 Hz of 2 x 106 cells from trypsin-dispersed monolayer cul-
ture in 50ml medium in Techne (Cambridge, UK) stirrer
flasks for 2-7 days under the same conditions.
Reagents
131I-mIBG with a specific activity of 37-185 MBq mg-', non-
radiolabelled mIBG and 3'I-sodium iodide were obtained
from Amersham International (Amersham, UK).
Experimental treatment
Experiments were carried out with both 'small' (approxi-
mately 250 tim diameter) and 'large' (approximately 400 jLm
diameter) neuroblastoma spheroids. Each experiment was
performed at least twice. Aliquots of spheroids were transfer-
red to 25 ml sterile plastic screw-topped vessels ('universal
containers') and allowed to settle. The supernatant was
removed and replaced with fresh medium containing '3'I-
mIBG. The concentrations of '31I-mIBG used initially were
1.2, 2.4, 3.6 and 4.8 MBq ml'. In order to determine the
'31I-mIBG concentration needed to cure more than 50% of
small spheroids, a concentration of 6.0 MBq ml-' was used
in addition. The spheroids and mIBG were then incubated
for 2 h with intermittent agitation at 37'C. This incubation
period was chosen because we have shown that accumulation
of mIBG by neuroblastoma spheroids increases up to this
time (Mairs et al., 1991a). Intermittent agitation was used in
preference to continuous stirring because it allowed use of a
smaller incubation volume and hence minimised the total
quantity of radiopharmaceutical required. We have previ-
ously demonstrated that this technique results in uniform
distribution of mIBG throughout neuroblastoma spheroids
(Mairs et al., 1991a). Following the incubation, the medium
was removed and spheroids were rinsed twice in phosphate
buffered saline to remove any unbound mIBG. Spheroids
were then immediately transferred individually by micro-
pipette into separate wells of a 24 well plate which had been
base coated with 1.25% Noble agar and contained 0.5 ml
supplemented medium. The plates were incubated at 37'C in
5% CO2, and 0.5 ml fresh medium was added to each well at
weekly intervals.
Endpoints
The cross sectional area of each spheroid was measured on
day zero and three times a week thereafter using a semi-
automated image analysis system coupled via a television
camera to an inverted optical microscope similar to that
described by Twentyman (1982). Measurements were con-
tinued until more than half the spheroids had reached
1000 Lm diameter or for three weeks. From these area
measurements, the diameter and volume of individual
spheroids was calculated assuming spherical geometry. In
order to compare the effects of treatment on spheroids in
different size ranges, data for spheroids with an initial
diameter outside the desired range were excluded from
analysis. For each experimental point, measurements of
12-24 spheroids were used to calculate the median volume,
from which curves of spheroid regrowth could be plotted.
From these data the time taken for a 10-fold increase in
volume (?lo) for both treated spheroids and control spheroids
from the same experiment was calculated. As observations
were performed during the exponential growth phase, the
volume doubling time (r2) for control spheroids could be
derived from the measured TIO value. The specific regrowth
delay could be calculated according to the formula:
specific regrowth delay = T10(treated -T?1(control)
Specific regrowth delay was used in preference to simple
regrowth delay to allow for the slight variation in control TjO
values observed in different experiments. As both 250 Lm and
400,sm spheroids exhibited the same exponential growth
kinetics during the period of observation, there was no
systematic difference in the values of T2 between the experi-
mental groups.
Specific regrowth delay can only be calculated if more than
half the spheroids regrow following treatment. Detailed
analysis using Monte Carlo methods has shown that calcula-
tion ofregrowth delay from the median value of observations
in which up to 50% of spheroids are cured are valid (Whel-
don & Brunton, 1982). This is because the 'cured' spheroids
are not lost to the analysis - even if assigned infinite growth
delays they contribute to the identification of the median of
the data set.
As an alternative endpoint the proportion of spheroids
'cured' by treatment was calculated. Spheroid 'cure' may be
determined experimentally in different ways. In the outgrowth
assay, spheroids are placed in regular tissue culture multi-
wells and observed for cellular outgrowth. Spheroids which
fail to form any cellular outgrowth are deemed to be 'cured'.
This assay requires surviving cells to form a colony and is
therefore similar to clonogenic assay, but does not require
disaggregation of the spheroid. Alternatively in the regrowth
assay spheroids are placed individually in agar-coated wells
to prevent adhesion to the base and measured regularly.
Spheroids which fail to achieve a certain volume increase
within a specified time are considered 'cured'. Although this
definition is of necessity somewhat arbitrary, it has been used
satisfactorily to define spheroid 'cure' by this group (e.g.
Wheldon et al., 1985) and others (e.g. Schwachofer et al.,
1989). There is no evidence to suggest that the results
obtained with the outgrowth assay differ materially from the
regrowth assay. In this study we elected to use the regrowth
assay as 'cure' rates may be determined on groups of
spheroids being observed for regrowth delay, whereas the
outgrowth assay would have required additional spheroids to
have been plated and observed separately. In this paper
spheroids were considered 'cured' if they failed to achieve a
5-fold volume increase in the duration of the experiment,
usually 3 weeks.
The endpoints of regrowth delay and 'cure' were chosen as
i
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a good correlation has been shown between tumour spheroid
radiosensitivity estimates derived from regrowth delay, cure
and clonogenic assays (Pourreau-Schneider & Malaise, 1981;
West et al., 1984; Moore et al., 1987).
Controls
In each experiment, the growth of untreated spheroids was
measured and compared with that of treated spheroids. To
show that any effect on spheroid growth was due to 31I-
mIBG, experiments were repeated using either non-radio-
labelled mIBG (1 mM and 2 mM), or '3'I-sodium iodide (1.2,
2.4, 3.6, 4.8 and 6.0 MBqml') in place of '31I-mIBG. In
addition, the effect of 2, 4, 6, 8 and 1OGy external beam
irradiation from a 60 Co teletherapy source on SK-N-BE(2c)
spheroids of different sizes was measured in the same way.
Doses larger than 6 Gy 'cured' too many spheroids of both
sizes to allow the specific regrowth delay to be calculated. To
establish whether there is any interaction between the
chemical, mIBG, and radiation, that is to see if mIBG acts as
a radiosensitiser, the effect of external beam irradiation on
spheroids incubated with non-radiolabelled mIBG was also
determined.
Statistics
Confidence intervals for medians were calculated according
to the method described by Campbell and Gardner (1989).
Proportions of small and large spheroids cured were com-
pared by a modification of Fisher's exact test (Campbell &
Machin, 1990).
Results
A concentration related cytotoxic effect of '3'I-mIBG on
SK-N-BE(2c) neuroblastoma spheroids was observed.
Typical regrowth curves for 400 1sm diameter spheroids
treated with 2.4, 3.6 and 4.8 MBq m'l 3I11-mIBG are shown
in Figure 2.
Figure 3 shows the specific regrowth delay of small and
large spheroids produced by '31I-mIBG. At a concentration
of 1.2 MBq ml-' no difference was seen. At 2.4 MBqml-'
the data points overlap, but the spread of values for large
spheroids suggests that the effect is greater than on small
spheroids. At 3.6 MBq ml-' there is a clear difference in the
specific regrowth delay between small and large spheroids,
with the latter being more affected. In two experiments on
large spheroids at this dose level the specific regrowth delay
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Figure 3 Specific regrowth delay achieved by different concent-
rations of 31'I-mIBG for 250 lim diameter spheroids (open
squares) and 400gim diameter spheroids (filled squares). The
symbols have been spaced out for clarity. Each point represents
the median and 95% confidence intervals of one experiment.
Arrowheads indicate that the upper confidence interval could not
be calculated as the corresponding Tio value exceeded the dura-
tion of the experiment. Stars indicate experiments with 400Am
spheroids where the specific regrowth delay could not be cal-
culated as too few spheroids regrew to derive a Tio value.
could not be calculated as too few spheroids regrew to permit
the derivation of a Tio value. At 4.8 MBqml-', the highest
concentration tested against 400jim diameter spheroids, too
many were 'cured' to quantify specific regrowth delay. At
6.0 MBq ml-', the highest concentration tested against
250jim diameter spheroids, too many were 'cured' to allow
calculation of specific regrowth delay values. Figure 3 shows
that an '3'I-mIBG concentration of only 3.6 MBqml-' is
required to produce a similar specific regrowth delay on
400 lim diameter spheroids as is produced by 4.8 MBqml-'
on 250gm diameter spheroids.
Figure 4 shows the proportion of small and large spheroids
cured at each dose level used. The data from all experiments
at each '3'I-mIBG concentration were pooled: the mean
number of individual spheroids used to calculate the value
for each point on this graph was 60. These results show that
4.8 MBq ml1' 'cures' a significantly greater proportion of
large than small spheroids (Xc2 = 55.9, P <0.001). The dose
required to cure 50% of spheroids (TCD50) was derived by
13"1-mlBG concentration (MBq ml-1)
Figure 4 Proportion of small spheroids (open squares) and large
spheroids (filled squares) 'cured' by increasing concentrations of
'31I-mIBG. Each point represents the pooled result of all
experiments.
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Figure 2 Representative regrowth curves for 400 iLm diameter
neuroblastoma spheroids following treatment with '3II-mIBG.
Median and 95% confidence intervals of at least 12 observations.
Symbols: filled square, untreated control, open square,
2.4 MBqml-'; filled triangle, 3.6 MBq ml-'; open triangle,
4.8 MBq ml-'.
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interpolation. For large spheroids the TC]
ml-', and for small spheroids 5.75 MBq
indicating the greater effect of "1I-mIBG oi
Spheroids treated with activities of'3'I-sc
6.0 MBq ml-' showed no regrowth dela:
'cured'. Similarly, no effect was seen on
with non-radiolabelled mIBG up to concei
which exceeds by a factor of four the ma
tions of '3'I-mIBG used. In addition, the
beam irradiation on spheroids incubatec
labelled mIBG was indistinguishable fror
external beam irradiation alone was used
It is deduced that the toxicity demonstral
the incorporation of radioactive mIBG by
cells, as these control experiments have sh4
be attributed to the '3'I or the mIBG
interaction between mIBG and radiation.
The specific regrowth delay produced
irradiation on small and large SK-N-BI
shown in Figure 5. As a given dose prodi
on spheroids of both sizes, it is deduced
seen with the targeted radiotherapy is di
characteristics of '31I.
Discussion
Although the sizes of spheroids chosen in
and 400g1m, are relatively close together, ti
difference in the absorbed fraction, 1, c
about 20% for the smaller and 30% for ti
(Figure 1), i.e. a 50% difference in d
predicted. While a greater difference perte
the order of a millimetre diameter are st
feasible with the tumour spheroid model.
is in practice at the upper limit of star
system, as SK-N-BE(2c) spheroids tend
their diameter approaches 1 mm.
If, for spheroids of a particular size, the
1, shown in Figure 1 is multiplied by ti
mIBG concentration (TCD_O) shown in Fig
obtained which should be proportional to
absorbed. If our predictions are correct,
'311-mIBG concentrations will result in simi
ation doses in spheroids of different sizes.
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Figure 5 Specific regrowth delay achieved
irradiation of small spheroids (open squares) a
(filled squares). Symbols are spaced out for
represents the result of one experiment. Tri;
radiation doses at which it was not possiblc
specific regrowth delay as too many spheroids
triangles, small spheroids; closed triangles, larn
les indicate the specific regrowth delay of sph
irradiation following incubation with non-rad
D50 was 4.15 MBq the product of b and TCD_o for small and large spheroids
ml-', also clearly respectively is similar. Thus the results obtained with our in
In larger spheroids. vitro model are close to what was predicted by mathematical
)dium iodide up to studies.
y and none were The prediction that smaller neuroblastoma micrometastases
spheroids treated are more difficult to cure with '3ll-mIBG has serious implica-
ntrations of 2 mM, tions for clinical practice. If targeted therapy cannot be relied
ximum concentra- upon to eradicate subclinical tumour deposits, '31I-mIBG
effect of external must be used as part of a strategy incorporating some other
1 with non-radio- way of sterilising microscopic disease.
n that seen when Widespread dissemination is a feature of neuroblastoma,
L(Figure 5). and part of the rationale for using biologically targeted
ted must be due to therapy. Bone marrow examination in such cases often
the neuroblastoma reveals micrometastases, sometimes just small clumps of cells
own that it cannot rather than larger aggregates. Our results predict that it is
alone nor to an these deposits which may lead to treatment failure, if undue
reliance is placed on `311-mIBG therapy. There are several
by external beam different ways in which this problem may be overcome,
E(2c) spheroids is including targeted therapy with alternative radionuclides, and
uces similar effects combination of '31I-mIBG with external beam radiotherapy.
that the difference Electronic equilibrium is achieved in smaller tumours than
ae to the physical is the case with 'l3I if radionuclides with emissions of a
shorter length are used. One such radionuclide which may
prove suitable is the longest lived isotope of the halogen
astatine, 2"'At. This emits alpha particles with a track length
of about 60 Lm, adequate to traverse several cell diameters
and so kill untargeted cells by cross fire, but short enough to
this study, 250tm be effective in small diameter micrometastases. In addition,
here is a significant the densely ionising, high linear energy transfer quality of
)f "'lI radiation - alpha particle radiation means that a lower dose is required
he larger spheroids to achieve the same effect as '3`I, and gives the added advant-
ose absorption is age of overcoming the resistance of hypoxic cells. If astatin-
ains if tumours of ated benzylguanidine can be produced, its optimal use might
tudied, this is not be in combination with '3'I-mIBG to achieve maximal levels
Four hundred ym of tumour cell kill for a range of sizes of micrometastases.
rting size for this An alternative approach, which is more practical at the
to disintegrate as present time, is to combine '31I-mIBG with external beam
total body irradiation (TBI). The TBI may eradicate smaller
absorbed fraction, tumour deposits in which there are fewer clonogenic cells,
ie isoeffective '3'I- although the dose limits imposed-by normal tissue tolerance
gure 4 a number is may prevent cure of larger deposits. If TBI is combined with
the radiation dose '3'I-mIBG therapy in the treatment of neuroblastoma, each
, then isoeffective modality may offset the disadvantages of the other (Wheldon
ilar absorbed radi- et al., 1988, 1991). An added benefit of this combined
At 1.15 and 1.25, strategy is that it should encompass all tumour deposits and
so reduce the importance of the problem of heterogeneity of
uptake in tumour which may occur with targeted radio-
pharmaceuticals. This phenomenon, which has not been
considered in the present analysis, will be of increasing
importance with larger tumours, and may be a limiting factor
A A A A in the targeted therapy of macroscopic tumours. However
A A A A experimental studies have shown that, in spheroids at least,
uniform distribution of mIBG does occur in contrast to the
marked heterogeneity seen with monoclonal antibodies
(Mairs et al., 1991a).
The optimal scheduling of targeted radiotherapy with TBI
has been investigated by O'Donoghue (1991). A set of com-
bined treatment schedules, chosen to be biologically equiva-
lent to a TBI course of seven 2 Gy fractions are evaluated.
The tumour effects ofthese schedules depend on the specificity
of targeting, represented by the ratio of the initial dose rate
for the tumour cells to that in the dose limiting normal
organ, and the heterogeneity of targeting represented by the
I, proportion oftumour cells that escape irradiation by targeted
8 10 radiotherapy. The optimal schedule predicted varies depend-
ing on these factors and the radiobiological parameters of the
tumour, but almost always requires a significant component
by external beam of TBI for maximum therapeutic effectiveness.
cadlarge spheroids In practice a combination regimen consisting of five 2 Gy
clarlty, each point fractions of TBI and "3'I-mIBG activity calculated for each
e to determine the patient to give a 4 Gy whole body dose (making a total of
were 'cured' (open 14 Gy whole body dose) is predicted to give a high pro-
ge spheroids). Circ- bability of sterilising subclinical neuroblastoma tumours in
ieroids achieved by all size classes. A clinical study to evaluate this strategy in
liolabelled mIBG. selected patients has recently commenced.1052 M.N. GAZE et al.
In conclusion, this study produces data indicating that if
targeted radiotherapy with '31I-mIBG is to be used success-
fully in patients with neuroblastoma, a means of overcoming
the relative resistance of micrometastatic disease needs to be
incorporated into the therapeutic strategy.
This work was supported by generous grants from The Neuro-
blastoma Society and The Cancer Research Campaign.
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